Physician profile
Mark Blackwelder
NPI 1245200880
$4,510.39
in general payments reported to CMS, 2019-2025
30 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $843 · 2021: $503 · 2022: $931 · 2023: $612 · 2024: $418 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.69 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $933.61 | 2019-2024 | Farxiga, Lokelma |
| Novo Nordisk INC | $763.47 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $616.23 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $425.88 | 2019-2024 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $366.64 | 2022-2025 | |
| Corcept Therapeutics | $196.98 | 2024-2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $175.51 | 2021-2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.18 | 2019-2023 | |
| Abbvie INC. | $111.96 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $109.77 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Vertos Medical, INC. | $91.04 | 2019 | |
| Glaxosmithkline, LLC. | $62.59 | 2021-2025 | Shingrix |
| Abbott Laboratories | $58.88 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.98 | 2022-2025 | Xifaxan |
| Insulet Corporation | $43.03 | 2024-2025 | Omnipod |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $38.20 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $37.11 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.94 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $30.48 | 2022-2025 | |
| Global Blood Therapeutics, INC. | $25.08 | 2022 | |
| Mylan Specialty L.P. | $23.98 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $19.94 | 2021 | |
| Inogen, INC. | $19.80 | 2023 | Inogen At Home Stationary Concentrator |
| Abiomed | $19.47 | 2025 | |
| Dexcom, INC. | $18.51 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $16.35 | 2020 | |
| Daiichi Sankyo INC. | $15.55 | 2022 | |
| Boston Scientific Corporation | $14.92 | 2023 | |
| Nevro Corp. | $14.58 | 2023 | Senza |
| Esperion Therapeutics, INC. | $12.73 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Blackwelder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.